Noninvasive Alzheimer's detection system
(event-related potentials)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
Neuronetrix announced the first test of the COGNISION™ System as part of the company’s pivotal multi-center clinical trial. The first subject was tested December 10th at the University of Kentucky’s Sanders-Brown Alzheimer’s Disease Center.
The multi-center study will evaluate Neuronetrix’s proprietary COGNISION™ System as a practical non-invasive test for the early detection of Alzheimer’s disease. In the ongoing study, dementia subjects who are presumed to have Alzheimer’s disease will be evaluated using a number of research protocols including magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, and a battery of psychometric tests. The dementia subjects will then undergo the 30 minute COGNISION™ Test which involves recording brainwaves while the subject listens to a series of auditory stimuli. Healthy control subjects will undergo a brief psychometric exam and then take the COGNISION™ Test. The COGNISION™ Software will then be trained to distinguish a healthy subject from one who might have Alzheimer’s disease.
“While several new technologies are being evaluated as diagnostic biomarkers of Alzheimer’s disease including PET imaging, MRI volumetry, and CSF analysis, only COGNISION™ holds the potential of a practical, reliable, and inexpensive Alzheimer’s test which can be administered in a doctor’s office,” said K.C. Fadem, President of Neuronetrix. Read more: neuronetrix.com
Orange juice flavanone: benefit to heart
Hesperidin, a flavanone found in orange juice, may significantly reduce blood pressure and other cardiovascular disease risk factors, according to a new study. Read more: nutraingredients.com
No comments:
Post a Comment